The Pharma giant Johnson & Johnson (JNJ ) has announced a strategic collaboration with Sail Biomedicines to develop next-generation treatments for autoimmune diseases using innovative in vivo CAR-T therapy.
As part of the Johnson & Johnson Sail Biomedicines partnership agreement, Johnson & Johnson will provide $785 million in initial payments, including a $465 million equity investment, with an additional $140 million tied to development milestones. JNJ has also secured an exclusive option to acquire Sail Biomedicines for $2.58 billion as a long-term goal.
The biotech partnership combines Johnson & Johnson’s global drug development expertise with Sail Biomedicines’ proprietary RNA-based platform to create potentially curative therapies that could transform treatments for immune-mediated diseases.
This investment further strengthens the J&J immunology pipeline while expanding the company’s presence in advanced cell therapy beyond cancer treatment.
The Vivo CAR-T Innovation In Johnson & Johnson Sail Biomedicines Partnership
The JNJ Partnership with Sail Biomedicines centers on advancing a new class of in vivo CAR-T therapies for immune-mediated diseases. CAR-T, or Chimeric Antigen Receptor T-cell therapy, is a type of immunotherapy that engineers a patient’s T cells (white blood cells responsible for fighting disease) to recognize and eliminate harmful cells.
Unlike conventional CAR-T therapy, which requires immune cells to be removed from a patient, modified in a laboratory, and then infused back, in vivo CAR-T aims to generate these therapeutic cells directly inside the patient’s body. This approach could simplify manufacturing, improve scalability, and make advanced therapies more accessible to a larger number of patients.
Through the Sail and JNJ Collaboration, the companies will initially develop Sail’s lead autoimmune disease program while exploring opportunities to expand the platform to additional disease targets over time.
Johnson & Johnson said the partnership aligns with its broader strategy of investing in technologies capable of delivering durable, disease-modifying treatments rather than therapies that only manage symptoms.
John Reed, Executive Vice President of Innovative Medicine Research & Development at Johnson & Johnson, emphasized the unmet medical need in autoimmune diseases, stating, “People living with serious immune-mediated diseases continue to need treatments that can deliver deeper, more durable disease control.” He added that Sail’s platform represents “an exciting new approach” that could harness the power of CAR-T therapy in a simpler and more scalable way.
Sail’s RNA Platform Expands Access to Advanced CAR-T Therapies
A key strength of the Johnson & Johnson Sail Biomedicines partnership lies in Sail’s proprietary technology platform. The biotechnology company, founded by Flagship Pioneering, is developing RNA-based medicines that deliver therapeutic instructions directly inside selected cells.
Sail’s RNA platform combines Endless RNA (eRNA™) technology, targeted nanoparticle delivery, and artificial intelligence (AI)-enabled design to create in vivo CAR-T therapies without the need for complex laboratory cell engineering. By integrating these technologies into a single development platform, Sail aims to precisely control which cells receive the therapy and how long therapeutic proteins are produced inside the body.
John D. Mendlein, Ph.D., Executive Chairman of Sail Biomedicines, said the collaboration reflects a shared vision for advancing autoimmune care.
“We believe In Vivo CAR-T therapies have the potential to create a disruptive paradigm shift—from chronic treatments to potentially curative medicines for patients with immune-mediated diseases.”
Sail Biomedicines Deal Strengthens J&J Immunology Pipeline
The Johnson & Johnson Sail Biomedicines partnership also represents a major strategic investment in the company’s future immunology portfolio.
Under the agreement, Johnson & Johnson will make:
- $785 million in upfront payments
- $465 million as an equity investment in Sail Biomedicines
- Up to $140 million in milestone-based development payments
- An exclusive option to acquire Sail for an additional $2.58 billion, subject to regulatory approvals and other conditions.
At the same time, Johnson & Johnson lowered its 2026 adjusted earnings forecast, with a combined financial impact of the Sail collaboration and its recently completed Firefly Bio acquisition.
Significance of Sail and JNJ Collaboration In Autoimmune Diseases
Autoimmune diseases, including conditions such as lupus, rheumatoid arthritis, and multiple sclerosis, occur when the immune system mistakenly attacks healthy tissues. Current therapies often suppress immune activity to reduce symptoms, but many patients continue to experience relapses or require lifelong treatment.
The CAR-T therapy from the Johnson & Johnson Sail Biomedicines partnership initiative seeks to address this challenge through an “immune reset”, where engineered immune cells help rebuild a healthier immune response. Researchers believe this strategy could potentially produce longer-lasting remission and reduce dependence on continuous medication.
Although in vivo CAR-T therapy is still in the early stages of development and will require extensive clinical testing before it reaches patients, the Sail and JNJ collaboration demonstrates how major pharmaceutical companies are investing in emerging technologies that could make advanced cell therapies more scalable and widely accessible.
